RVPHW Projected Dividend Yield

Wt Exp 12/25/2025/Reviva Pharmaceuticals Holdings Inc ( NASDAQ : RVPHW )

Reviva Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company. Co.'s pipeline has two drug candidates, brilaroxazine (RP5063) and RP1208. Co.'s main drug candidate, brilaroxazine, is in clinical development and is intended to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis. Furthermore, brilaroxazine is for two respiratory indications, pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Co.'s RP1208 is for the treatment of depression and obesity.

20 YEAR PERFORMANCE RESULTS